In vitro and in vivo experiments have demonstrated that the enhancement of endogenous Trx expression and administration of exogenous Trx inducers play neuroprotective roles in AD, such as inhibiting oxidative stress, inflammation, and apoptosis, and activating survival signaling pathways. This evidence concerns the gene TXN and Alzheimer disease.